AstraZeneca: new approval for Fasenra in the USA

(CercleFinance.com) - AstraZeneca today announced US approval of Fasenra as an adjunctive treatment for severe eosinophilic asthma in children aged six to 11.


This approval by the US FDA follows the green light already given by the health agency to the drug in 2017, but in children aged over 12.

Fasenra is a monoclonal antibody that generates killer cells for eosinophils, the white blood cells found in half of all asthma patients.

Fasenra comes in a pre-filled syringe for subcutaneous injection once every four weeks for the first three doses, then once every eight weeks thereafter.


Copyright (c) 2024 CercleFinance.com. All rights reserved.